⌘K

13:20:00·378d

PRReleasevia Quantisnow

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

ByQuantisnow·Wall Street's wire, on your screen.

NUVB· Nuvation Bio Inc.

Health Care

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Related

CHIEF PEOPLE OFFICER Markel Stacy exercised 125,000 shares at a strike of $1.83 and sold $753,188 worth of shares (125,000 units at $6.03) as part of a pre-agreed trading plan (SEC Form 4)
CHIEF REGULATORY OFFICER Wentworth Kerry exercised 63,000 shares at a strike of $2.93 and sold $379,191 worth of shares (63,000 units at $6.02) as part of a pre-agreed trading plan (SEC Form 4)
Chief Financial Officer Sauvage Philippe exercised 47,668 shares at a strike of $2.17 and sold $286,370 worth of shares (47,668 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)
SEC Form 144 filed by Nuvation Bio Inc.
SEC Form 144 filed by Nuvation Bio Inc.